SCHEMBL6134430

SCHEMBL6134430

Cc1ccc(S(=O)(=O)NC(=O)c2ccc3nc(C)n(Cc4ccc(OCC5CCCCC5)cc4Cl)c3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.50
BCL2L1 Q07817 1/20 0.50
MCL1 Q07820 1/20 0.50
ALOX5AP P20292 4/20 0.41
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
CD4 P01730 2/20 0.37
CHEK2 O96017 2/20 0.37
ALDH1A1 P00352 2/20 0.37
VDR P11473 1/20 0.37
NR1H4 Q96RI1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6301270 0.99 PPARG (0.51) PPARGBCL2L1MCL1ALOX5APHDAC3
SCHEMBL27544222 0.90 PPARG (0.51) PPARGBCL2L1MCL1ALOX5APHDAC3
SCHEMBL7652842 0.88 PPARG (0.57) PPARGBCL2L1MCL1HDAC3HDAC4
SCHEMBL6301424 0.87 BCL2L1 (0.45) PPARGBCL2L1MCL1ALOX5APCD4
SCHEMBL6301141 0.86 PPARG (0.58) PPARGBCL2L1MCL1HDAC3HDAC4
SCHEMBL6301136 0.86 PPARG (0.62) PPARGBCL2L1MCL1HDAC3HDAC4
SCHEMBL6307796 0.86 PPARG (0.54) PPARGBCL2L1MCL1HDAC3HDAC4
SCHEMBL6303634 0.86 PPARG (0.57) PPARGHDAC3HDAC4HDAC1HDAC7
SCHEMBL6300850 0.86 BCL2L1 (0.43) PPARGBCL2L1MCL1ALOX5APCD4
SCHEMBL6133675 0.86 PPARG (0.71) PPARGBCL2L1MCL1ALOX5APHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP claimed
WO-2005082414-A2 CONCOMITANT DRUGS OF A SULFONAMIDE AND ANOTHER THERAPEUTIC AGENT ASTELLAS PHARMA INC. (JP) 2005-09-09 WO disclosed
US-20050197376-A1 Concomitant drugs FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-09-08 US disclosed
CN-1135224-C Benzimidazole derivatives ����ҩƷ��ҵ��ʽ���� 2004-01-21 CN disclosed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
CN-1268123-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2000-09-27 CN disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed